In low-risk acute coronary syndrome (ACS) patients, early treatment with ticagrelor (Brilinta) provides more rigorous platelet inhibition after ad hoc percutaneous coronary intervention (PCI) than clopidogrel (Plavix) use, a pharmacodynamics study showed.